Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
about
Concepts and clinical use of ultra-long basal insulinInsulin therapy for the treatment of type 1 diabetes during pregnancyModern basal insulin analogs: An incomplete storyPatient safety and minimizing risk with insulin administration - role of insulin degludecUpdate on the treatment of type 2 diabetes mellitusPharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.Clinical utility of insulin and insulin analogs.Personalized pharmacotherapy in diabetes care using clinical pharmacology data of basal insulin analogues.Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.Identifying and meeting the challenges of insulin therapy in type 2 diabetes.Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients.Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics.Insulin detemir for the treatment of obese patients with type 2 diabetes.Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patientsHalf-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrierĀ® insulin.Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1.Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabeteSafety and effectiveness of insulin detemir in different age-groups in the a1chieve study.Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients.The role of insulin detemir in overweight type 2 diabetes management.Determining effective insulin analog therapy based on the individualized needs of patients with type 2 diabetes mellitus.Hyperglycemia management in the hospital: about glucose targets and process improvements.Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes.Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT).Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled InsulinHow pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.Basal insulin: physiology, pharmacology, and clinical implications.Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.Cost-effectiveness of insulin detemir: a systematic review.Intensifying treatment of type 2 diabetes mellitus: adding insulin.Intensifying insulin treatment: options, practical issues, and the role of the nurse practitioner.
P2860
Q26770354-77D28B3A-9BFD-4EFB-96A8-DEB29809A0BEQ26829977-21358458-8F99-41F2-8EBF-65F8061ACCC4Q27015047-4158B9F1-4CF0-4FBD-93B3-8AAC3A448B47Q27025548-4C12ACDB-D5AA-4334-8B85-2B562B468858Q28073342-C1D00E62-F6FE-4828-B43A-AA265CC80043Q30248803-D8E23E65-E75E-4CFF-B087-0C1ABF4FBCDAQ30429358-9A3F8FE8-1187-4C00-A576-0446FE2B3EA0Q30809002-EB3BDA73-677B-4501-A4C3-523AA6E24CC3Q33603473-45B4998D-F80E-479D-A7AC-9987AE6602F7Q33863413-DF6479BF-42AB-44E0-8C4C-CEF1DF9D70B6Q34421048-13F863C7-ADED-42F3-89E1-10FAF38731FCQ34468769-AC997824-CB44-4933-9445-520FFA18B4FDQ34583351-40BB636C-97CC-4BD4-BA43-40BDAB6C3DDAQ34620581-65D3EBB6-2899-4EDC-AFF5-9CF26BC751E8Q35703041-1B7C4985-C883-4683-8F70-B4442FEB2F1BQ35786400-99C7BC27-43C8-45C7-8F41-86EBCFA0421AQ35918397-B68C7D31-CF62-4D18-9895-70FD2395105AQ36637960-47548357-3C24-4E8D-9D16-10BC7D968EE0Q36792962-F5191F8B-0D5E-4189-811A-D802AEC146E8Q36796725-21CC34ED-B13F-4AF3-98B9-F361E127DD98Q36869489-F18FF624-AE3C-4433-9241-D9E57B0EFDD3Q36941711-D85F1850-8656-4AE3-A0B6-A6C8E101A6CAQ36947990-04F5DECD-196A-4981-967A-8F7BACDC7B17Q37022851-05DC26DE-27CA-46FA-A15B-792C64D559D8Q37167565-80977643-B5C4-4348-ADE9-98C5E430F522Q37199308-ED47E62E-78F2-4B59-81F9-097BCD6961BDQ37248234-DC594A77-1E43-405D-90E8-82943A89E100Q37281598-B2D923A2-76DE-4798-B5DA-C7F40E501ED7Q37329881-12A0579E-F251-454C-AF6B-A007A772076EQ37405567-AAA29111-54EB-4ECB-8CFB-40D1D0BAE342Q37561045-FFA20969-31C5-4C13-8EBF-03662CFB8697Q37594353-52B1895C-91D5-42C4-B248-DF805B65431CQ37670097-1968AE4C-8090-46CA-8DC6-EB6C946AC6C7Q37732207-91A1C5BC-E000-4CA7-B789-A8200EB05A5EQ37771436-B4BF955A-9DA0-4CD9-9B17-5D8BD993535EQ37890774-EEAB456D-EBE7-42CA-B985-80DB9E8A2D52Q37893971-22B6BCE2-6EF7-4732-AB4D-98B49416F066Q37941075-C1A79982-5FEE-4F9A-A104-28BA65F487A3Q37961849-32B8F649-A577-4F41-A79B-24CD33979BBDQ38008006-2148A29A-940B-4804-B721-38949A4AD304
P2860
Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
description
2007 nĆ® lÅ«n-bĆ»n
@nan
2007幓ć®č«ę
@ja
2007幓č«ę
@yue
2007幓č«ę
@zh-hant
2007幓č«ę
@zh-hk
2007幓č«ę
@zh-mo
2007幓č«ę
@zh-tw
2007幓č®ŗę
@wuu
2007幓č®ŗę
@zh
2007幓č®ŗę
@zh-cn
name
Towards peakless, reproducible ...... on isoglycaemic clamp studies.
@en
type
label
Towards peakless, reproducible ...... on isoglycaemic clamp studies.
@en
prefLabel
Towards peakless, reproducible ...... on isoglycaemic clamp studies.
@en
P1476
Towards peakless, reproducible ...... on isoglycaemic clamp studies.
@en
P2093
P304
P356
10.1111/J.1463-1326.2007.00756.X
P577
2007-07-21T00:00:00Z